Ross Procedure Emerges as a New Gold Standard for Young Patients Requiring Aortic Valve Replacement
Ross Procedure Emerges as a New Gold Standard for Young Patients Requiring Aortic Valve Replacement
Source: Journal of the American College of Cardiology, published online June 23, 2026.
• In a high-volume Ross center (455 patients), 12-year survival matched that of the age-matched general population.
• Excellent durability:
* Aortic valve reintervention: 1.1% at 12 years.
* Any cardiac reintervention: 3.5%.
• Outstanding hemodynamic performance:
* Mean aortic valve gradient: 4 mmHg at 12 years.
* No prosthesis–patient mismatch.
• Permanent pacemaker implantation: only 0.8%.
• Outcomes were similar in patients >50 and <50 years.
• The Ross procedure replaces the diseased aortic valve with the patient’s own pulmonary valve (living autograft), providing near-normal valve function, preserving exercise capacity, avoiding lifelong anticoagulation in most patients, and potentially restoring normal life expectancy.
• In carefully selected patients, Ross may provide superior long-term survival and valve performance compared with conventional prosthetic valve replacement.
• Key limitation: Excellent outcomes depend on careful patient selection and experienced, high-volume Ross centers; broader adoption requires standardized quality metrics and surgical expertise.
• Despite accumulating evidence, the Ross procedure remains a Class IIb recommendation in the 2020 ACC/AHA Valvular Heart Disease Guideline, although many experts anticipate stronger recommendations in future guideline updates.
Take-home message: For appropriately selected patients—particularly younger adults treated at experienced Ross centers—the Ross procedure is increasingly emerging as the benchmark surgical option for aortic valve replacement.
https://www.jacc.org/doi/10.1016/j.jacc.2026.04.046